Iris Garrido-Cano
10PUBLICATIONS
19CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (10)
Sort by Publication Date:
|Apr 10, 2026
Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer.Ana Lameirinhas, Paula Díez, Francisco J Hicke
|Aug 22, 2024
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas
|Sep 28, 2023
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.Marta Tapia, Cristina Hernando, María Teresa Martínez
|Aug 07, 2023
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy.Iris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas
|Feb 25, 2023
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano
|Aug 07, 2021
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.Cristina Hernando, Belén Ortega-Morillo, Marta Tapia
Pageof 2
Frequent Collaborators
4 joint publications
Pilar Eroles
3 joint publications
Cristina Hernando
2 joint publications
Ana Lameirinhas
2 joint publications
Ana Lluch
2 joint publications
María Teresa Martínez
2 joint publications
Eduardo Tormo
2 joint publications
Ramón Martínez-Máñez
2 joint publications
Sandra Torres-Ruiz
2 joint publications
Juan Miguel Cejalvo
1 joint publications
Vera Constâncio
